Ravn
Senior Member (Voting Rights)
https://www.ncbi.nlm.nih.gov/pubmed/29100842 (paywalled)
2018 Jan;3(1):17-24. doi: 10.1016/S2468-1253(17)30338-2. Epub 2017 Nov 1.
Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
This Danish article discusses the above study:
https://videnskab.dk/krop-sundhed/n...brugt-til-behandling-af-irritabel-tarmsyndrom (Danish)
Primarily the study is about fecal transplants for IBS. Results mixed. Short-term beneficial effects but few lasting effects. Best outcomes for patients with only IBS and no comorbidities.
But one interesting point is made for ME: patients with IBS and with comorbidities “like fibromyalgia, Chronic Fatigue Syndrome ME/CFS or depression, often experienced little or no effect above placebo”.
2018 Jan;3(1):17-24. doi: 10.1016/S2468-1253(17)30338-2. Epub 2017 Nov 1.
Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
This Danish article discusses the above study:
https://videnskab.dk/krop-sundhed/n...brugt-til-behandling-af-irritabel-tarmsyndrom (Danish)
Primarily the study is about fecal transplants for IBS. Results mixed. Short-term beneficial effects but few lasting effects. Best outcomes for patients with only IBS and no comorbidities.
But one interesting point is made for ME: patients with IBS and with comorbidities “like fibromyalgia, Chronic Fatigue Syndrome ME/CFS or depression, often experienced little or no effect above placebo”.
Det viste sig, at patienter, der havde flere lidelser, som fibromyalgi, kronisk træthedssyndrom ME/CFS eller depression, ofte oplevede en lille eller ingen effekt udover placeboeffekten.